Editas Beats Q4 EPS by 21c, R&D Revenues $24.7M, Cash Runway to 2027
Editas reported a Q4 loss of $0.06 per share, beating the consensus by $0.21, as R&D expenses dropped 44% to $27.4 million. Collaboration revenues reached $24.7 million, a 19% year-over-year decline but $17.7 million above forecasts, and $146.6 million in cash funds operations into Q3 2027.
1. Q4 Financial Highlights
Editas posted a fourth-quarter loss of $0.06 per share versus a consensus loss of $0.27, driven by revenue of $24.7 million that surpassed forecasts by $17.7 million despite a 19% year-over-year decline due to prior-year milestone recognitions.
2. Expense Reductions
R&D expenses fell 44% to $27.4 million and general and administrative costs dropped 31% to $11.4 million, while restructuring and impairment adjustments produced a $6.3 million benefit compared with a $12.2 million charge a year earlier.
3. Cash Position and Pipeline Outlook
With $146.6 million in cash and investments as of year-end, Editas expects funding into Q3 2027; the company is advancing its lead in vivo candidate EDIT-401 toward an IND filing by mid-2026 and first human studies by late 2026.